ASCO/EHA/ICML 2023 – Alessandra Tedeschi
Alessandra Tedeschi gives insights into the health-related quality of life data from the ASPEN study conducted in patients with Waldenström macroglobulinemia, discusses the notable results from the extended follow-up of the SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia as well as the clinical activity of zanubrutinib in the setting of R/R marginal zone lymphoma while finally depicting her personal highlights from this year’s EHA congress.
Here is the full ASCO/EHA/ICML 2023 report.
More posts
Preface – ASCO/EHA/ICML 2023
Cutting-edge updates in the diagnosis and treatment of hematological malignancies were discussed by world-leading experts at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, 2nd–6th June 2023, the European Hematology Association (EHA) congress in Frankfurt, Germany, 8th–11th June 2023, and the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, 13th–17th June 2023.